Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Fort Dodge licenses vaccine stem cells:

Fort Dodge Animal Health has gained the rights to an embryonic-derived stem cell line to evaluate it for use in the production of a viral vaccine. The cell line, called ebx, was developed by Vivalis, a biotechnology company based in Nantes, France. Vivalis was set up by Groupe Grimaud, which became the second-largest global specialist in avian genetics after acquiring Merial's avian genetics division in 2005 (Animal Pharm No 562, p 5). Franck Grimaud, chief executive of Vivalis, said: "We firmly believe that Vivalis' chicken and duck ebx cell lines could be an attractive alternative to embryonated eggs for the industrial production of viral vaccines."


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts